Additional file 2 of Insights into treatment-specific prognostic somatic mutations in NSCLC from the AACR NSCLC GENIE BPC cohort analysis
Creators: name: Liu, Yi
name: Yalavarthi, Sindhu
name: Yang, Fan
name: Abdul-Rashid, Yusif
name: Tang, Shenkun
name: Long, Zihe
name: Qin, Yongkai
name: Wu, Kerui
name: Wang, Zhifei
Publisher: name: figshare
Year: 2024
Subjects: subject: Medicine
subject: Genetics
subject: FOS: Biological sciences
subject: Molecular Biology
subject: Pharmacology
subject: Cancer
subject: Infectious Diseases
subject: FOS: Health sciences
subject: Plant Biology
subject: Virology
subject: Computational Biology

description: Supplementary Material 2: Supplementary Figure 1. Progression-free survival (PFS) of patients treated with a platinum-based regimen with or without bevacizumab.A-C. Kaplan–Meier survival analysis illustrating PFS for patients treated with carboplatin + pemetrexed, cisplatin + pemetrexed, and stage V patients treated with cisplatin + pemetrexed, respectively, with or without bevacizumab. Significance was assessed using the log-rank test. Supplementary Figure 2. Prognostic impact of the mutation signature for immune checkpoint inhibitor (ICI) therapy in EGFR, KRAS, or TP53 mutant or wild-type (WT) patients. Progression-free survival (PFS) of patients categorized into Positive, Negative, or Neutral groups based on the mutational signature status of ICI therapy in (A) EGFR, (B) KRAS, and (C) TP53 WT or mutant cases, assessed using the Kaplan–Meier method with log-rank test. Supplementary Figure 3. Prognostic impact of the mutation signature in carboplatin-based chemotherapy in KRAS or TP53 mutant or wild-type (WT) patients. Progression-free survival (PFS) of patients categorized into Negative or Neutral groups based on the mutational signature status of carboplatin-based chemotherapy in (A) KRAS and (B) TP53 WT or mutant cases, assessed using the Kaplan–Meier method with log-rank test. Supplementary Figure 4. Prognostic impact of the mutation signature in cisplatin-based chemotherapy in KRAS or TP53 mutant or wild-type (WT) patients. Progression-free survival (PFS) of patients categorized into Negative or Neutral groups based on the mutational signature status of cisplatin-based chemotherapy in (A) KRAS and (B) TP53 WT or mutant cases, assessed using the Kaplan–Meier method with log-rank test. Supplementary Figure 5. Prognostic impact of the mutation signature in pemetrexed-based chemotherapy. A. Progression-free survival (PFS) of patients treated with pemetrexed monotherapy, categorized into Negative or Neutral groups based on the mutational signature status, assessed using the Kaplan–Meier method with a log-rank test. B-C. PFS of patients treated with pemetrexed-based chemotherapy, categorized into Negative or Neutral groups based on the mutational signature status in (B) KRAS and (C) TP53 WT or mutant cases, assessed using the Kaplan–Meier method with log-rank test. Supplementary Figure 6. Prognostic impact of the mutation signature in docetaxel-based chemotherapy. Progression-free survival (PFS) of patients treated with docetaxel-based chemotherapy, categorized into Negative or Neutral groups based on the mutational signature status of (A) KRAS and (B) TP53 wild-type (WT) or mutant cases, assessed using the Kaplan–Meier method with a log-rank test.